Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.59 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.59 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5009615 | 0.99 | KCNH2 (0.58) | KCNH2NR4A2IRAK4MKNK1TAAR1 | |
| SCHEMBL14584483 | 0.85 | NR4A2 (0.56) | KCNH2NR4A2IRAK4MKNK1MAPT | |
| SCHEMBL7985049 | 0.81 | KCNH2 (0.65) | KCNH2NR4A2IRAK4MKNK1 | |
| Hydrochloric Acid SCHEMBL11478170 | 0.81 | KCNH2 (0.51) | KCNH2RAB9AMAPTALDH1A1HTT | |
| SCHEMBL9534952 | 0.81 | KCNH2 (0.61) | KCNH2NR4A2MAPTALDH1A1CYP1A2 | |
| SCHEMBL6991613 | 0.79 | KCNH2 (0.59) | KCNH2NR4A2ALDH1A1TSHRKMT2A | |
| SCHEMBL11265895 | 0.79 | KCNH2 (0.83) | KCNH2NR4A2MAPTALDH1A1HTT | |
| SCHEMBL7981124 | 0.79 | KCNH2 (0.61) | KCNH2NR4A2IRAK4MKNK1MAPT | |
| SCHEMBL7971741 | 0.79 | KCNH2 (0.61) | KCNH2NR4A2IRAK4MKNK1ALDH1A1 | |
| SCHEMBL7971742 | 0.79 | KCNH2 (0.61) | KCNH2NR4A2IRAK4MKNK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7390811-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-06-24 | — | — | US | disclosed |
| US-7361657-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-04-22 | — | — | US | disclosed |
| US-7173034-B2 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-06 | — | — | US | disclosed |
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-25 | — | — | US | disclosed |
| EP-0920425-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-0888336-B1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)P IPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6211199-B1 | HISTAMINE AND TACHYKININ RECEPTOR ANTAGONISTS; ANTIASTHMATICS, ANTIEMETICS; RESPIRATORY SYSTEM DISORDERS, INFLAMMATORY BOWEL DISEASE, CONJUNCTIVITIS | AVENTIS PHARMACEUTICALS INC. | 2001-04-03 | — | — | US | disclosed |
| US-5922737-A | Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021410-A1 | Respiratory syncytial virus replication inhibitors | CCNA1, CCNB3, CCNI | KCNH2 1071/4885NR4A2 1140/4885IRAK4 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.